ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
ChromaDex Corporation

ChromaDex Corporation (CDXC)

3.67
-0.17
(-4.43%)
Closed March 27 04:00PM
3.55
-0.12
( -3.27% )
Pre Market: 08:52AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.55
Bid
3.55
Ask
3.61
Volume
1,340
0.00 Day's Range 0.00
1.25 52 Week Range 4.0598
Market Cap
Previous Close
3.67
Open
-
Last Trade Time
08:52:40
Financial Volume
-
VWAP
-
Average Volume (3m)
223,146
Shares Outstanding
75,309,118
Dividend Yield
-
PE Ratio
-16.71
Earnings Per Share (EPS)
-0.22
Revenue
72.05M
Net Profit
-16.54M

About ChromaDex Corporation

ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship in... ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. It delivers Niagen as the sole active ingredient in its consumer product namely, Tru Niagen which is available on Tru Niagen's website and through partnerships with retailers and distributors. Show more

Sector
Medicinal Chems,botanicl Pds
Industry
Medicinal Chems,botanicl Pds
Headquarters
Dover, Delaware, USA
Founded
1970
ChromaDex Corporation is listed in the Medicinal Chems,botanicl Pds sector of the NASDAQ with ticker CDXC. The last closing price for ChromaDex was $3.67. Over the last year, ChromaDex shares have traded in a share price range of $ 1.25 to $ 4.0598.

ChromaDex currently has 75,309,118 shares outstanding. The market capitalization of ChromaDex is $276.38 million. ChromaDex has a price to earnings ratio (PE ratio) of -16.71.

CDXC Latest News

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport®) are Alkemist Assured ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine...

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss...

Form 8-K - Current report

0001386570FALSE00013865702024-03-062024-03-06UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 8-KCURRENT REPORTPursuant to Section 13 OR 15(d) of The Securities Exchange...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

0001386570falseFY2023http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613MemberP3Y0.33330.33330.33330.33330.333300013865702023-01-012023-12-3100013865702023-06-30iso4217:USD00013865702024-0...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to...

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.5618.729096992.994.05982.956186643.63821422CS
41.84107.6023391811.714.05981.575284422.87653051CS
122.07139.8648648651.484.05981.362231462.63219821CS
262.1144.8275862071.454.05981.251441532.28732852CS
521.97124.6835443041.584.05981.251189941.98743904CS
156-5.32-59.97745208578.8711.21.153228454.51030493CS
260-0.47-11.69154228864.0223.661.154828038.39213181CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 20.75
(336.84%)
2.22M
XLOXilio Therapeutics Inc
$ 1.99
(211.42%)
9.04M
AKANAkanda Corporation
$ 0.3235
(96.18%)
15.48M
PIKKidpik Corporation
$ 6.19
(89.30%)
4.04M
BCGBinah Capital Group Inc
$ 15.50
(63.16%)
190.9k
NCNANuCana PLC
$ 0.24
(-21.73%)
128.95k
GMDAGamida Cell Ltd
$ 0.047
(-20.61%)
8.02M
WAVDWaveDancer Inc
$ 2.93
(-18.61%)
11
MLKNMillerKnoll Inc
$ 24.91
(-18.41%)
72.25k
INOInovio Pharmaceuticals Inc New
$ 10.65
(-18.27%)
320
KTRAKintara Therapeutics Inc
$ 0.1062
(18.66%)
18.24M
AKANAkanda Corporation
$ 0.3235
(96.18%)
15.6M
AKBAAkebia Therapeutics Inc
$ 2.48
(10.71%)
12.83M
CISSC3is Inc
$ 0.0334
(-12.57%)
12.19M
XLOXilio Therapeutics Inc
$ 1.97
(208.29%)
9.07M

CDXC Discussion

View Posts
Sirpeter Sirpeter 6 days ago
Beast...almost no shares out
👍️0
Sirpeter Sirpeter 1 week ago
Buying at this level...
👍️0
Sirpeter Sirpeter 1 week ago
..will let you know after your're done licking my balls



👍️0
TrendTrade2016 TrendTrade2016 1 week ago
are you licking your wounds under a rock somewhere on your otc scams..lmao
👍️0
Monksdream Monksdream 1 week ago
CDXC new 52=week hi
👍️0
TrendTrade2016 TrendTrade2016 1 week ago
CDXC...BIO BEASTING...HERE COMES 3 DOLLA
👍️0
TrendTrade2016 TrendTrade2016 1 week ago
MOVE A LONG MAGGOT
👍️0
Sirpeter Sirpeter 1 week ago
Go ahead buy it way up there bird brain
👍️0
TrendTrade2016 TrendTrade2016 1 week ago
CDXC...HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 1 week ago
CDXC..THE NEXT BIO BEAST READY TO BEAST THROUGH THE STREETS
👍️0
Golden Cross Golden Cross 2 weeks ago
$3 Next
🤡 1 🤢 1
TrendTrade2016 TrendTrade2016 2 weeks ago
CDXC,,,NEXT WEEK WEEKLY BLITZ
👍️0
Monksdream Monksdream 2 weeks ago
CDXC new 52 week hi
👍️0
Monksdream Monksdream 1 month ago
CDXC under $2
👍️0
Monksdream Monksdream 6 months ago
CDXC under $2
👍️0
R9CC R9CC 10 months ago
Law firms looking into it the matter:
https://thebrios.com/chromadex-corporation-investors-investigation/
👍️0
oilin07 oilin07 1 year ago
https://healthnews.com/longevity/longevity-supplements/can-nmn-supplements-cause-cancer/
👍️0
tat4tat tat4tat 1 year ago
Article on Google trending news indicated that this supplement could cause breast cancer leading to brain cancer and death.
👍️0
KMBJN KMBJN 1 year ago
Hey frrol! Good luck with AVXL, and NGENF, each with promising neuroprotective drugs, like NR. Such a tricky space (neurodegeneration in general), but with such a great need and potentially huge reward.

Some anti-amyloid antibody trials have failed in Alzheimer's recently, and some have reported more promising results. I think that gene regulation for amyloid and tau knockdown are also very promising avenues to pursue.

I wonder what the recent news of NMN being taken away as a supplement by FDA will do for NR supplement business, or if/when CDXC will be moving on to the second generation NAD+ boosters, which seem much more potent (and hopefully the IP is really locked away!). Still trying to understand the results and implications of all the lawsuits with Elysium on CDXC's NR business, but it seems like those are all winding down and nothing much good came of it all for CDXC.

https://www.naturalproductsinsider.com/regulatory/trade-groups-react-fda-decision-%CE%B2-nmn-supplements
👍️0
frrol frrol 1 year ago
Saw that article too, this weekend. Finding may be valid. As you point out, a lot of uncertainty, and more research needed. And could be nothing. Good to hear from you! Still got my AVXL. Big readout in 2 weeks....
👍️0
KMBJN KMBJN 1 year ago
How time passes by so quickly. So many ups and downs in biotech, and "the science" is often very slow to play out, or at least for a company to prove they can sell something useful at a profit. Wish I would've learned to sell more on spikes we've had (though I did get my basis out here above $20). Any ways, just a follow up here regarding the possible cancer issue by NR:

insert-text-here

Lastly, we used BiNR to investigate the role of NR uptake in cancer prevalence and metastases formation in triple negative breast cancer (TNBC) animal model. Our results demonstrate that NR supplementation results in a significant increase in cancer prevalence and metastases of TNBC to the brain. These results outline the important role of powerful nutraceuticals like NR in cancer metabolism and the need to personalize their use in certain patient populations.

I don't know how to test this in the real world, except perhaps to do a case control study of those taking NR and looking at incidence of cancer.

It's possible the mouse M TNBC model does not apply to humans.
👍️0
tredenwater2 tredenwater2 2 years ago
Just wanted to post occasionally so the spambots dont crowd out the board. They have a way of crowding everyone else out. This looks like a likely condition or “play” for a buyout. Most likely a 50% premium from here looks ggggggrrreeeeaaat!

Happy Fathers day!
👍️0
tredenwater2 tredenwater2 2 years ago
This supplement could cause peace in the Middle East and it is still going to go down. Wow, talk about an easy takeover with revenue here! Are the 3 “billionaires” buying more?
👍️0
tredenwater2 tredenwater2 2 years ago
Testing one, two,…this stock has flatlined! Wheres the revenue from Wallymart or in the Asian market where this supplement was booming? Are the 3 billionaires still increasing their positions? Must be the Covid curse that killed the rally.

Anecdotally my wife has been on this supplement now for approx 120 days and her endometriosis pain has completely gone away. This is a major blessing and if for no other reason a reason to stay on this supplement for life!
👍️0
someconcerns someconcerns 3 years ago
Yes, agreed. It is however one of those carefully constructed short theses which, while it won't influence a long who has done extensive DD, can easily influence someone who is in this casually. It clearly did not move the markets much this morning.
👍️0
tat4tat tat4tat 3 years ago
Just read it. Wouldnt short after getting product into Walmart.
👍️0
someconcerns someconcerns 3 years ago
Short-oriented blurb on SA today, based on a detailed short piece by some entity called JCap. Can't post it but there was a link in the SA piece.
👍️0
tat4tat tat4tat 3 years ago
Saw Tru Niagen at Walmart the other day.
👍️0
tredenwater2 tredenwater2 3 years ago
Make no mistake this company’s stock is under accumulation! Its all about the benjamin’s and with yesterdays news release, and prior anticipation, Tru Niagens revenue should increase for Chromadex. Walmart wouldnt of been my first guess but it is better than sitting in a small health food store obscure in and amongst 500 other unknown supplements. The kicker is once on the store shelves they need to do a pr blitz on human efficacy in trials. I will also be interested to see the cost of each bottle as its easily available on Amazon and at Chromadex website and even cheaper if you sign up for autoship.

I am currently taking the supplement again and have committed to a minimum of 90 days to see if I benefit. I had an issue with my sleep which I am now sure had nothing to do with tru niagen but hard to continue dolling out $$ and not sleeping.

With any decent positive earnings increase Imo this company is being set up for a buyout. If I had more available funds I would dip a toe back in but right now I am riding Avxl’s horse and Rett syndrome approval followed by Parkinsons data leading into Alheimers as the grand follow up…I like the return where Im presently at better.

Cheers
👍️0
Roadtojourney Roadtojourney 3 years ago
Still confused as to how can this be down on such a great news and many junk stocks are up on no news?? Imo
👍️0
Roadtojourney Roadtojourney 3 years ago
Is the news fake or what?? Or is it dump on news pos??
👍️0
tredenwater2 tredenwater2 3 years ago
Recent hire with a Nestle connection and has developed products for Asia. Interesting as we are doing really well in Asia and partnered with Nestle.

Jmho
👍️0
jfk jfk 3 years ago
Wow, quite a historical piece of DD. I don't think they are working any longer with P&G. Would be nice, but pretty sure they are out of the picture. Let me know if you've heard differently.
👍️0
tredenwater2 tredenwater2 3 years ago
Here you go

https://www.bizjournals.com/cincinnati/news/2015/11/12/p-g-inks-deal-with-maker-of-age-defying-ingredient.html

Tred
👍️0
jfk jfk 3 years ago
P&G?
Nestle is still wrestling with solubility issues (for nutrition drinks). If they ever figure that out, then we are moving forward in a significant way. Until then, its a slog.
👍️0
tredenwater2 tredenwater2 3 years ago
Great points JfK. Their normal model does seem to target a different consumer. Their must be value for the customer and a profit in their models to give up shelf space. I will have to look into their 2 different price point products they are selling.

Also P&G and Nestle are signed on, seems like this is going to “blanket” saturate the market pretty soon and in doing so must have good solid data to do so. Profits should follow.

3 billionaires and 3 major Brands pursuing Tru Niagen.......it must have passed the smell test!
👍️0
jfk jfk 3 years ago
I have to believe that WalMart is only taking this because they were advised there are some major studies with expected quite positive results that can be leveraged 2H21, and/or they plan on making a major strategic push to put money and marketing knowhow behind healthy supplementation of diet and lifestyle....as part of 'up-scaling' their customer base. Otherwise, this doesn't make sense. TruNiagen does not currently fit with their customer base, and the TruNiagen target market would not be aware of TruNiagen being stocked in a WalMart type retailer. I do curbside pickup from WMT each week, and as a regular customer they are not soliciting me with ads of any kind. Something doesn't seem right, and I hope that WMT has very good reasons to bring this item in.
👍️0
tredenwater2 tredenwater2 3 years ago
Some nice attempts to stea...grab some shares these days. 3,000 walmart stores is a nice chunk of change with not one but two price points? Must be, buy 3 and watch out for the “falling prices”. Walmart doesnt normally let just any product on their shelf. If not a takeover target before Q3 or more importantly Q4, we should have some impressive revenue ramp up.
👍️0
someconcerns someconcerns 3 years ago
Congrats. I should have sold more of my shares when I could early on. Plan to buy back the shares I did sell.
👍️0
TheBullTwit TheBullTwit 3 years ago
A tidy profit of around 400% of invested price if they have been selling into this volume.

I guess I missed my prediction on the top today but it did hit $22 pre-market. I closed my short at $18 - could have gotten another $4 out of it I see now. didn't think it would drop this fast today.
👍️0
someconcerns someconcerns 3 years ago
13G filing, which I think relates to the earlier $25MM stock placement:

http://archive.fast-edgar.com/20210226/AWZGJ22CW222R2C2222M22Z2FSTRZ22I9232
👍️0
TheBullTwit TheBullTwit 3 years ago
I think it will hit yesterday’s AH high just under 25 and then settle down

I might scalp a small short at 23 but will watch.
👍️0
someconcerns someconcerns 3 years ago
Bull, what price levels does your model show?
👍️0
TheBullTwit TheBullTwit 3 years ago
The price and volume action looks very much like a high volume trap here. Fund the company, convert the shares, sell into Hugh volume spike.

I’d look to see this possibly run at the high one more time today and then start to
Drop back toward 10.
👍️0
tredenwater2 tredenwater2 3 years ago
I believe I read some time back Proctor and
Gamble is partnered as well for a line of products.
👍️0
someconcerns someconcerns 3 years ago
Would not be surprised by a buyout. They already have a commercial relationship with nestle for adding NR to nestle products. Time will tell. No rush on my part.
👍️0
Skidoonut Skidoonut 3 years ago
Then I'm also sure you noticed the amended form 4s issued at the beginning of November of last year? If you haven't take a look at the date the options are exercisable, because it's today's date. I would not call myself accredited at all, I should not be listened to for advice in any way. However I have a certain feeling that a buyout not a hostile takeover is in the works here, I would not be surprised at all if a offer has been made here....

Do your own DD!
👍️0
someconcerns someconcerns 3 years ago
I myself am an accredited investor, most of the time investing in not-yet-listed non-public companies. So the buyers are willing to wait a while and I'm sure there were some non-publicized understandings about what conditions have to be met before the non-public shares have their (probably) section 144 restriction removed. They clearly have confidence in CDXC.

I've been going thru weeks of rigamarole getting my restrictions lifted on another stock.
👍️0
Skidoonut Skidoonut 3 years ago
While that press release is great news, I was referencing the actual 8-k. Most specifically the last paragraph that states,

"The Shares are not registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws. The Company has relied on the exemption from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. In connection with the Purchaser’s execution of the Purchase Agreement, the Purchaser represented to the Company that it is an “accredited investor” as defined in Regulation D of the Securities Act and that the Shares purchased were acquired solely for its own account and for investment purposes and not with a view to the future sale or distribution." 

👍️0
ClayTrader ClayTrader 3 years ago
* * $CDXC Video Chart 02-25-2021 * *

Link to Video - click here to watch the technical chart video

👍️0

Your Recent History

Delayed Upgrade Clock